Skip to main content

Table 3 Quality of Life measures

From: A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss

Variable

Treatment Group

LLLT (N = 15)

Lorcaserin (N = 14)

Combination (N = 13a)

LASA ± SD

 Baseline

8.0 ± 0.9

7.7 ± 1.8

7.4 ± 1.1

 Week 12

8.6 ± 0.9

8.6 ± 0.8

8.2 ± 1.3

 Delta

+0.6 ± 0.9b

+0.9 ± 1.9

+0.8 ± 1.2b

CES-D ± SD

 Baseline

2.0 ± 3.6

4.1 ± 6.6

2.8 ± 3.3

 Week 12

3.3 ± 4.4

3.7 ± 4.3

3.4 ± 2.8

 Delta

+1.3 ± 2.5

−0.4 ± 4.8

+0.6 ± 2.8

BAS ± SD

 Baseline

3.7 ± 0.6

3.7 ± 0.5

3.7 ± 0.7

 Week 12

3.6 ± 0.5

3.9 ± 0.7

3.8 ± 0.8

 Delta

−0.1 ± 0.6

+0.3 ± 0.4b

+0.1 ± 0.7

BASS ± SD

 Baseline

3.0 ± 0.4

3.0 ± 0.5

3.0 ± 0.4

 Week 12

3.1 ± 0.3

3.3 ± 0.5

3.0 ± 0.8

 Delta

+0.1 ± 0.4

+0.3 ± 0.4b

0.0 ± 0.6

IWQOL - TOTAL ± SD

 Baseline

54.1 ± 12.1

50.9 ± 15.3

62.8 ± 22.4

 Week 12

47.9 ± 7.4

47.6 ± 15.6

54.9 ± 21.9

 Delta

−6.1 ± 10.4

−3.3 ± 8.7

−8.0 ± 7.9c

  1. BAS Body Appreciation Scale, BASS Body Area Satisfaction Scale, CESD-R Center for Epidemiologic Studies Depression Scale Revised, IWQOL-Lite Impact of Weight on Quality of Life - Lite, LASA Linear Analogue Self-Assessment, SD Standard Deviation
  2. aOf the 15 subjects assigned to the combination group, 2 discontinued prior to week 12 and are not included in the analysis
  3. b P < 0.05 for paired t-test comparing week 12 versus baseline
  4. c P < 0.01 for paired t-test comparing week 12 versus baseline
Back to article page

BMC Obesity

ISSN: 2052-9538

Contact us